Home
Finance & valuation

Finance & valuation

SVB’s collapse is a reminder of how far IP finance still has to travel

Like many others, the bank held thousands of patents as security for loan deals, but almost certainly had no idea of their value – or lack of it

The Market Makers of 2022: top 20 revealed

Marconi's Kasim Alfalahi takes the top spot for Avanci's stellar showing in our countdown of the patent market’s most innovative and influential dealmakers and decision takers

Patent litigation finance skyrockets in past three years

We compiled data from Westfleet Advisors’ annual litigation funding reports to find patent finance shot up by nearly 50% since 2020 – to the benefit of rights holders

Latest content

A big buyer two years ago, Chinese company on entity list moves portfolio off its books

O-Film, a smartphone supplier that has counted Apple among its clients, spins 900+ assets to a related party as its business comes under pressure

26 January 2021

Chinese lidar manufacturer paid $20 million upfront plus ongoing royalties to settle Velodyne dispute

Hesai Photonics Technology reveals monetary details of settlement, which also involves ongoing royalty payments through 2030

22 January 2021

Six life sciences IP dealmaking trends to watch out for in 2021

Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year

19 January 2021

Subsidies still matter in China’s patent world, but focus is shifting overseas

USPTO report on non-market patent incentives shows how Chinese applicants are being encouraged to obtain more foreign rights

14 January 2021

South Korea's Intellectual Discovery is in the process of becoming a big league, mainstream NPE

A year after a major capital infusion and a change of leadership, the firm has notched some notable settlements in the US and laid the groundwork for new assertion campaigns

08 January 2021

LG Electronics hooks up with IP Bridge as fund looks beyond Japan

Licensing business that shed state sponsorship last year partners with Korean patent powerhouse in latest acquisition

05 January 2021

The keys to effective IP monetisation

Patent licensing is as much an art as it is a science, explain some of those featured in the new IAM Strategy 300 Global Leaders guide

22 December 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies.

22 December 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver

16 December 2020

It’s time for investors to re-assess intangibles

A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models

12 December 2020

Unlock unlimited access to all IAM content